Xynomic Pharmaceuticals Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 12

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

Xynomic Pharmaceuticals General Information

Description

Developer of anti-tumor drugs aims to build a clinical and pre-clinical stage oncology pipeline targeting cancers. The company focuses on in-licensing, developing, and commercializing oncology drug candidates, enabling the company to develop drugs in a cost and time-efficient manner.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 13029 Danielson Street
  • Suite 120
  • Poway, CA 92064
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Xu-Nuo Pharma
Vertical(s)
Corporate Office
  • 13029 Danielson Street
  • Suite 120
  • Poway, CA 92064
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xynomic Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 17-Jun-2021 Completed Generating Revenue
5. PIPE 14-May-2019 Completed Pre-Clinical Trials
4. Reverse Merger 14-May-2019 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 04-Jun-2018 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 01-Feb-2017 $4.3M $4.8M Completed Startup
1. Seed Round $500K $500K Completed Startup
To view Xynomic Pharmaceuticals’s complete valuation and funding history, request access »

Xynomic Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Angel 23,435,379 $0.000100 8% $0.02 $0.02 1x $0.02 23.8%
To view Xynomic Pharmaceuticals’s complete cap table history, request access »

Xynomic Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of anti-tumor drugs aims to build a clinical and pre-clinical stage oncology pipeline targeting cancers. The c
Drug Discovery
Poway, CA
12 As of 2024

Palo Alto, CA
 

San Carlos, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xynomic Pharmaceuticals Competitors (112)

One of Xynomic Pharmaceuticals’s 112 competitors is Immune-Onc Therapeutics, a Venture Capital-Backed company based in Palo Alto, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immune-Onc Therapeutics Venture Capital-Backed Palo Alto, CA
Iovance Biotherapeutics Corporation San Carlos, CA
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom
Adimab Venture Capital-Backed Lebanon, NH
Lite Strategy Corporation San Diego, CA
You’re viewing 5 of 112 competitors. Get the full list »

Xynomic Pharmaceuticals Patents

Xynomic Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2021501199-A Crystalline salt of b-raf kinase inhibitor Active 26-Oct-2017
JP-2023062074-A Crystalline salt of b-raf kinase inhibitor Pending 26-Oct-2017
JP-7230041-B2 Crystalline salt of b-raf kinase inhibitor Active 26-Oct-2017
AU-2018355528-A1 Crystalline salts of a b-raf kinase inhibitor Active 26-Oct-2017
AU-2018355528-B2 Crystalline salts of a b-raf kinase inhibitor Active 26-Oct-2017 C07D471/04
To view Xynomic Pharmaceuticals’s complete patent history, request access »

Xynomic Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xynomic Pharmaceuticals Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bison Capital Acquisition Special Purpose Acquisition Company (SPAC) Minority
EarlyBirdCapital Investment Bank Minority
Hakim Unique Corporation Minority
Northern Light Venture Capital Venture Capital Minority
Prosperico Ventures Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Xynomic Pharmaceuticals Investments & Acquisitions (2)

Xynomic Pharmaceuticals’s most recent deal was a Merger/Acquisition with Bison Capital Acquisition. The deal was made on 15-May-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Bison Capital Acquisition 15-May-2019 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
Boehringer Ingelheim (BI 882370 Global rights) 30-Oct-2017 Corporate Asset Purchase Buildings and Property
To view Xynomic Pharmaceuticals’s complete investments and acquisitions history, request access »

Xynomic Pharmaceuticals FAQs

  • When was Xynomic Pharmaceuticals founded?

    Xynomic Pharmaceuticals was founded in 2016.

  • Where is Xynomic Pharmaceuticals headquartered?

    Xynomic Pharmaceuticals is headquartered in Poway, CA.

  • What is the size of Xynomic Pharmaceuticals?

    Xynomic Pharmaceuticals has 12 total employees.

  • What industry is Xynomic Pharmaceuticals in?

    Xynomic Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Xynomic Pharmaceuticals a private or public company?

    Xynomic Pharmaceuticals is a Private company.

  • What is Xynomic Pharmaceuticals’s current revenue?

    The current revenue for Xynomic Pharmaceuticals is .

  • How much funding has Xynomic Pharmaceuticals raised over time?

    Xynomic Pharmaceuticals has raised $21.8M.

  • Who are Xynomic Pharmaceuticals’s investors?

    Bison Capital Acquisition, EarlyBirdCapital, Hakim Unique, Northern Light Venture Capital, and Prosperico Ventures are 5 of 7 investors who have invested in Xynomic Pharmaceuticals.

  • Who are Xynomic Pharmaceuticals’s competitors?

    Immune-Onc Therapeutics, Iovance Biotherapeutics, Sygnature Discovery, Adimab, and Lite Strategy are some of the 112 competitors of Xynomic Pharmaceuticals.

  • When was Xynomic Pharmaceuticals acquired?

    Xynomic Pharmaceuticals was acquired on 17-Jun-2021.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process